Early-stage biotech companies present new approaches to attacking solid tumors. These companies are driving advances in cell and gene therapy for solid tumors including glioblastoma and pancreatic cancer but there are significant challenges in raising capital – who will take the lead to advance early biotech programs in solid tumors so other investors will follow?Read more
Can new models of financing allow solid tumor research and development to move more quickly? Non-profits are willing to place their bets on new ideas that may not otherwise be funded. Corporate ventures are moving into earlier research. Consortia are leveraging funds to remove roadblocks and drive efficiencies to get to the clinic faster. Take […]Read more
In cell and gene therapy, the patient is both the process and the product. What are the challenges faced by companies in building new drug development teams and processes to meet the requirements of cell and gene therapy? How has your company adjusted to cell and gene product approval requirements, reimbursement, access and manufacturing challenges?Read more
Lunch Keynote Panel Discussion: Cancer in Common – Patients, Caregivers, Doctors, Nurses, Advocates, Researchers, Me, You. We All Have cancer in Common.
To cure cancer, we must connect scientists, companies, clinicians, payers, patients and caregivers by sharing the challenges we face and what inspires us to overcome them. This panel will share stories of challenges, of hope, of breakthroughs–of the moments that matter and propel us forward in the common experience of cancer.Read more
Glioblastoma is one the deadliest cancers. With current treatment depending on surgery’s and chemotherapy’s limited benefits, we desperately need new approaches and new therapies. Can breakthroughs in next-generation CAR T-cells, suicide genes, oncolytic viruses and others change the outlook for people with the toughest- to-treat cancers?Read more
Pancreatic cancer needs new treatments that give patients years of benefit, rather than months – hear from pioneers of leading-edge research, patient advocates, and biotech leaders who are providing “hope for all stages” for pancreatic cancer patients.Read more